Latest Asx Compliance News

Botala Energy Ltd has denied holding undisclosed information following a sharp share price rise, linking the spike to a recent Serowe CBM Project announcement and confirming compliance with ASX disclosure rules.

Litchfield Minerals denies undisclosed material information behind recent share price jump, pointing to public engagement, media activity, and early-stage exploration sample processing as key influences.

Key Petroleum Ltd has wrapped up the last 3% tranche of its share placement, raising nearly $59,000 and exhausting its 15% ASX placement limit. The fresh capital is earmarked for asset acquisitions, development, and working capital.

Papyrus Australia (ASX: PPY) has secured $175,000 through a share placement alongside convertible note conversions and related party loans, aiming to fund commercialisation and fulfil a key contract for biodegradable Collar Keeper® products.

Gateway Mining attributes recent share price gains to a newly published independent research report, while confirming ongoing assay results from its Yandal Project remain under review and will be disclosed progressively starting 22 April 2026.

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

Emu NL's EMUOA securities have been suspended from trading by the ASX, pending compliance with listing rules. This move affects only the EMUOA class and signals regulatory scrutiny ahead of the company's next steps.

Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.

ION Video Ltd has responded to ASX inquiries by confirming its recent discussions with Meta Platforms and Alphabet remain preliminary, with no binding agreements or commercial terms agreed. The company emphasised that the engagements are exploratory and non-binding, explaining why earlier disclosure was not required.

Rhythm Biosciences has clarified inconsistencies in its disclosures around termination events in its underwriting agreement for RHYO options, following an ASX query. The company acknowledged an incomplete initial summary and administrative oversights but confirmed the agreement remains in full effect.

Tarrina Resources (ASX: TR8) has addressed ASX’s query on recent share price movement, confirming it has dispatched soil and drill core samples for laboratory testing with results expected by late April. The company maintains strict confidentiality protocols and affirms compliance with continuous disclosure rules.

Holista Colltech’s shares remain suspended on the ASX following a trading halt linked to ongoing legal issues with ProImmune Company LLC, with no resolution in sight.